Cambridge Heart Reports Results for the Second Quarter 2008
Cambridge Heart Welcomes Louis Blumberg to the Board of Directors
Microvolt T-Wave Alternans Found to Be Highly Accurate Predictor...
CMS Reaffirms National Coverage Determination For Microvolt T-Wave Alternans
Cambridge Heart Reports Results for the First Quarter 2008
Medicare Coverage for Microvolt T-Wave Alternans Testing; Patented Analytic Spectral Method Required
Premera Blue Cross Covers Microvolt T-Wave Alternans Testing
Cambridge Heart Releases Statement by Dr. Theodore Chow on MTWA Testing
ALPHA Supports Use of MTWA Risk Stratification in Non-Ischemic Heart Failure
Largest Prospective Study of Microvolt T-Wave Alternans in Patients with Non-ischemic Cardiomyopathy Confirms the Predictive Value of MTWA
Largest Prospective Study of Microvolt T-Wave Alternans Demonstrates This Technology's Predictive Value
Clinical Trial Demonstrates that MTWA Test is Comparable to Invasive Tests in Identifying Patients Who Could Benefit from ICDs
Read the article from Nature Clinical Practice Cardiovascular Medicine, ?Can microvolt T-wave alternans testing reduce unnecessary defibrillator implantation??
More news...
 

HearTwave® II Microvolt T-Wave Alternans System ... In the news

A New System at Carolina East Cardiology
Carolina East Cardiology in Greenville introduces its HearTwave II system to the public. Click here to view the story.

On the WNCT video page, scroll down the story list to the "New Cardiac Tool at Carolina East Cardiology" story. Click it and the video launches.

 
  Copyright ©1999-2008 Cambridge Heart, Inc